Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Cancer
|
September 26, 2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors
R T Penson, J G Supko, M V Seiden, et al.
Gynecologic Oncology
|
July 4, 2012
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
N S Horowitz, A B Olawaiye, D R Borger, et al.
British Journal of Cancer
|
June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
R T Penson, M V Seiden, U A Matulonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 1999
Phase I study of Doxil and vinorelbine in metastatic breast cancer
H J Burstein, M J Ramirez, W P Petros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Docetaxel administered on a weekly basis for metastatic breast cancer
H J Burstein, J Manola, J Younger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U A Matulonis, R T Penson, S M Domchek, et al.
Gynecologic Oncology
|
February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin
C N Krasner, C Castro, R T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
R. T. Penson, K. Kronish, Z. Duan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Cancer
|
September 26, 2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors
R T Penson, J G Supko, M V Seiden, et al.
Gynecologic Oncology
|
July 4, 2012
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva
N S Horowitz, A B Olawaiye, D R Borger, et al.
British Journal of Cancer
|
June 30, 2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
R T Penson, M V Seiden, U A Matulonis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 1999
Phase I study of Doxil and vinorelbine in metastatic breast cancer
H J Burstein, M J Ramirez, W P Petros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Docetaxel administered on a weekly basis for metastatic breast cancer
H J Burstein, J Manola, J Younger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2016
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U A Matulonis, R T Penson, S M Domchek, et al.
Gynecologic Oncology
|
February 16, 2019
Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin
C N Krasner, C Castro, R T Penson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 10, 2001
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
R. T. Penson, K. Kronish, Z. Duan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J F Liu, W T Barry, M Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 3